肾功能与血液透析对血浆血管加压素及和肽素水平的影响
本研究在127例不同分期慢性肾脏病患者(含42例血液透析患者)及16名健康人中观察和肽素与血管加压素水平。发现肾功能越低两者水平越高;eGFR>28 ml/min/1.73 m²时C/V比值稳定,eGFR≤28 ml/min/1.73 m²时C/V比值随肾功能恶化而升高。透析中血管加压素清除率高于和肽素,导致C/V比值升高。
要点
- eGFR>28 ml/min/1.73 m²时和肽素可可靠替代血管加压素。
- eGFR≤28 ml/min/1.73 m²(CKD 4-5期)需校正肾功能。
- 透析中和肽素水平不能充分反映血管加压素水平。
核心结论
- eGFR>28 ml/min/1.73 m²时和肽素是血管加压素的可靠替代物。
- eGFR≤28 ml/min/1.73 m²时流行病学研究需校正肾功能。
- 透析中和肽素水平不能充分反映血管加压素水平。
研究设计与样本
- 观察性研究,纳入127例不同分期CKD患者(含42例血液透析患者)和16名健康人。
- 采用线性(分段)回归分析评估肾功能与和肽素、血管加压素及C/V比值的关联。
- 计算血液透析对和肽素和血管加压素的清除率。
主要发现
- 肾功能越低,和肽素和血管加压素水平均越高,且均与血浆渗透压相关。
- eGFR>28 ml/min/1.73 m²时C/V比值稳定;eGFR≤28 ml/min/1.73 m²时C/V比值随肾功能恶化而升高。
- 透析中血管加压素初始下降幅度大于和肽素,C/V比值升高,部分因血管加压素透析清除率更高。
关键数值与推荐
- eGFR>28 ml/min/1.73 m²时C/V比值稳定。
- eGFR≤28 ml/min/1.73 m²时C/V比值随肾功能恶化而升高。
临床怎么用
- eGFR>28 ml/min/1.73 m²时可用和肽素替代血管加压素。
- eGFR≤28 ml/min/1.73 m²时使用和肽素需校正肾功能。
- 透析中不宜用和肽素水平反映血管加压素水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Copeptin is increasingly used in epidemiological studies as a substitute for vasopressin. The effect of renal function per se on copeptin and vasopressin concentrations as well as their ratio have, however, not been well described. METHODS: Copeptin and vasopressin levels were measured in 127 patients with various stages of chronic kidney disease, including 42 hemodialysis patients and 16 healthy participants in this observational study. Linear (segmental) regression analyses were performed to assess the association between renal function and copeptin, vasopressin and the C/V ratio. In addition, clearance of copeptin and vasopressin by hemodialysis was calculated. RESULTS: Both copeptin and vasopressin levels were higher when renal function was lower, and both showed associations with plasma osmolality. The C/V ratio was stable across renal function in subjects with an eGFR >28 ml/min per 1.73 m2. In contrast, the C/V ratio increased with worsening renal function in patients with eGFR ≤28 ml/min per 1.73 m2. During hemodialysis, the initial decrease in vasopressin levels was greater compared with copeptin and, consequently, the C/V ratio increased. This was, at least in part, explained by a greater dialytic clearance of vasopressin compared with copeptin. DISCUSSION: Our data indicate that copeptin is a reliable substitute for vasopressin in subjects with an eGFR >28 ml/min per 1.73 m2, whereas at an eGFR ≤28 ml/min per 1.73 m2, that is, CKD stages 4 and 5, a correction for renal function is required in epidemiological studies that use copeptin as a marker for vasopressin. Intradialytic copeptin levels do not adequately reflect vasopressin levels because vasopressin clearance by hemodialysis is higher than that of copeptin.
引用
- Ettema EM, Heida J, Casteleijn NF, et al. The Effect of Renal Function and Hemodialysis Treatment on Plasma Vasopressin and Copeptin Levels. Kidney Int Rep. 2017. PMID: 29142968. doi:10.1016/j.ekir.2017.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。